Viatris Inc. Q3 2026 Earnings Recap

Viatris shares fell 1.3% after earnings, a roughly flat reaction. The quarter showed growth and the company raised guidance midpoints, while the announced Pacira acquisition and several pipeline programs remain execution-dependent.

Key Takeaways

• Q3 revenue was $3.75 billion, adjusted EBITDA was $1.2 billion, and adjusted EPS was $0.71.
• For the first nine months, revenue grew 2%, adjusted EBITDA 6%, and adjusted EPS 8% operationally year over year.
• Viatris narrowed its 2026 guidance ranges and raised the midpoint for all key financial metrics, citing performance and expected fourth-quarter momentum.
• North America and Greater China were growth areas; management pointed to estradiol patches and injectable launches in North America, and cardiovascular products and established brands in China.
• The proposed Pacira acquisition would add EXPAREL and ZILRETTA and, if completed, is expected to take U.S. innovative medicines revenue above $1 billion in 2027.